طب القلب والأوعية الدموية

بالأسفل التجارب السريرية الحالية.

غربل قائمة الدراسات هذه بالموقع والحالة وغيرها.

1. International Bicuspid Aortic Valve Consortium (BAVCon)

   Rochester, Minn.

   Bicuspid aortic valve (BAV) disease is the most frequent congenital cardiac malformation, occurring in 0.5-1.2% of the US population. In young adults, it is generally a benign abnormality; but in older adults it is associated with thoracic aortic aneurysm or dissection in 20-30% of those with BAV. BAV is strongly associated with early development of aortic valve calcification or incompetence in >50% of BAV patients, and accounts for ~40% of the >30,000 aortic valve replacements (AVR) performed in the US each year. Yet, we know little of the etiology, cellular events and modifiers of progression of BAV to calcific aortic valve disease and we still do not understand the genetic cause(s) of BAV despite evidence for its high heritability.

   The Specific Aims of this study are:

   1. To identify the genetic causes of bicuspid aortic valve disease and its associated thoracic aortic disease.

   2. To identify potential pathways to predict the clinical course of BAV disease and for treating human BAV disease.

   To achieve these aims, we have created the International Bicuspid Aortic Valve Consortium (BAVCon), a consortium of institutions with cohorts of BAV patients and the expertise to fulfill the performance of these aims.

2. Autologous Induced Pluripotent Stem Cells of Cardiac Lineage Delivered Into Heart Muscle for Congenital Heart Disease

   Rochester, Minn.

   The purpose of this study to test the feasibility and safety for autologous (from your own body) skin cells that are manufactured into stem cells of cardiac lineage to be delivered into the heart muscle to determine if those stem cells will strengthen the heart muscle and can be used as an additional treatment for the management of  congenital heart disease. 

3. Genotype-Phenotype Correlation in Cardiovascular Disease

   Rochester, Minn.

   This research study is being done to help characterize cardiovascular disease and improve diagnostic tests.

   OBJECTIVES

   1. To understand the pathogenesis, molecular mechanisms, and disease progression of heritable cardiovascular disease

   2. To evaluate the incidence of occult heritable cardiovascular disease in various populations.

   3. To correlate imaging and pathological phenotype with genotype to the ends described above.

4. A Study to Assess the Role of Biomarkers in Risk Stratification in Adults with Congenital Heart Disease

   Rochester, Minn.

   The purporse of this study is to determine if biomarker assay obtained at baseline can predict future risk of cardiovascular adverse events, and to  determine if temporal changes in biomarker levels can provide a better risk prediction compared to biomarker assay obtained at baseline.

5. A Study to Evaluate Potential Myocardial Injury Following Magnetic Resonance Imaging (MRI)

   Rochester, Minn.

   The purpose of this study is to prospectively determine if magnetic resonance imaging (MRI) in patients with cardiac implantable electronic devices (CIED) results in myocardial injury as assessed by changes in high sensitivity cardiac troponin T (hs-cTnT) assay. This will be done by comparing pre-and-post MRI hs-cTnT levels in these patients.

6. Echocardiographic Measures of Pulmonary Vascular Distensibility and Effects on Lung Diffusing Capacity

   Rochester, Minn.

   The purpose of this study is to determine if the change in pulmonary vascular compliance with positional changes (upright, supine, and Trendelenburg position) is different in younger versus older individuals.

7. Prospective Identification of Long QT Syndrome in Fetal Life

   Rochester, Minn.

   The postnatal diagnosis of Long QT Syndrome (LQTS) is suggested by a prolonged QT interval on 12 lead electrocardiogram (ECG),a positive family history and/or characteristic arrhythmias and confirmed by genetic testing.  LQTS testing cannot be performed successfully before birth as   fetal ECG is not possible and direct measure of the fetal QT interval by magnetocardiography is limited. Genetic testing can be performed in utero, but there is risk to the pregnancy and the fetus. Although some fetuses present with arrhythmias easily recognized as LQTS (torsade des pointes (TdP) and/or 2° atrioventricular (AV) block, this is uncommon, occurring in <25% of fetal LQTS cases. Rather, the most common presentation of fetal LQTS is sinus bradycardia, a subtle rhythm disturbance that often is unappreciated to be abnormal. Consequently, the majority of LQTS cases are unsuspected and undiagnosed during fetal life, with dire consequences. For example, maternal medications commonly used during pregnancy can prolong the fetal QT interval and may provoke lethal fetal ventricular arrhythmias. But the most significant consequence is the missed opportunity for primary prevention of life threatening ventricular arrhythmias after birth because the infant is not suspected to have LQTS before birth. The over-arching goal of the study is to overcome the barriers to prenatal detection of LQTS. The investigators plan to do so by developing an algorithm using fetal heart rate (FHR) which will discriminate fetuses with or without LQTS. Immediate Goal: The investigators propose a multicenter pre-birth observational cohort study to develop a Fetal Heart Rate (FHR)/Gestational Age (GA) algorithm from a cohort of fetuses recruited from 13 national and international centers where one parent is known by prior genetic testing to have a mutation in one of the common LQTS genes: potassium voltage-gated channel subfamily Q member 1 (KCNQ1), potassium voltage-gated channel subfamily H member 2 (KCNH2), or sodium voltage-gated channel alpha subunit 5 (SCN5A). The investigators have chosen this population because 1) These mutations are the most common genetic causes of LQTS, and 2) Offspring will have high risk of LQTS as inheritance of these LQTS gene mutations is autosomal dominant. Thus, progeny of parents with a known mutation are at high (50%) risk of having the same parental LQTS mutation. The algorithm will be developed using FHR measured serially throughout pregnancy. All offspring will undergo postnatal genetic testing for the parental mutation as the gold standard for diagnosing the presence or absence of LQTS.

8. Study of Awareness and Detection of Familial Hypercholesterolemia (CASCADE-FH)

   Rochester, Minn.

   The CASCADE Familial Hypercholesterolemia Registry will track therapy, clinical outcomes, and patient-reported outcomes over time aiming to increase familial hypercholesterolemia awareness, promote optimal disease management, and improve outcomes. This study is not recruiting family members of FH patients at this time.

9. Angiographic and Psychosocial Evaluation of Peripartum vs. Non Peripartum Spontaneous Coronary Artery Dissection (SCAD

   Rochester, Minn.

   The purpose of this study is to determine differences in clinical and imaging presentation, in-hospital management and prognosis in peri-partum and non-peri-partum SCAD patients.

    

10. A Study of the Effect of Myectomy on the Sudden Cardiac Death Risk in Hypertrophic Cardiomyopathy

    Rochester, Minn.

    The primary purpose/objective of this study is to determine whether myectomy as a management option for severe hypertrophic cardiomyopathy (HCM) reduces the incidence of sudden cardiac death.